Pathogenesis of Guillain–Barré syndrome

Pharmacoeconomics of therapy for Guillain–Barré syndrome: plasma exchange and intravenous immunoglobulin

“…Diagnostic criteria were defined for research purposes in 1981 1 and have been subsequently refined. [12][13][14] Essentially, diagnosis requires progressive weakness in more than one limb over a period of less than 4 weeks, which is thought to be due to a neuropathy in the absence of any identifiable genetic, metabolic or toxic cause.…”

How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?

“…These antibodies have been reported in 30% to 80% of patients with MMN [8,9,11,13,36,37], but also in some patients with other immune-mediated neuropathy [7,38] and in 5% to 10% of patients with MND [8,36,[39][40][41]. Even if the role of anti-GM1 antibodies in distinguishing MMN from MND was confirmed in two large studies including a metaanalysis [10,11], this aspect remains controversial and testing for this antibodies was not included among the possible supportive laboratory test for the diagnosis of MMN by the American Association of Electrodiagnostic Medicine [42] while they were by the EFNS/PNS [23].…”

Paraneoplastic syndromes of the peripheral nerves

“…Once limited to acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and the Miller Fisher variant, Guillain-Barré syndrome (GBS) now also includes acute motor axonal neuropathy and acute motor sensory axonal neuropathy [10,11]. Hodgkin's lymphoma has been the cancer most often associated with GBS; the relationship to other malignancies is less clear [12].…”